InspireMD (NYSE:NSPR – Get Free Report) and Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for InspireMD and Interpace Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
| Interpace Biosciences | 0 | 0 | 0 | 0 | 0.00 |
InspireMD currently has a consensus target price of $4.50, indicating a potential upside of 400.00%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Interpace Biosciences.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InspireMD | $10.85 million | 3.89 | -$19.92 million | ($0.73) | -1.23 |
| Interpace Biosciences | $38.73 million | 0.21 | $24.58 million | ($0.05) | -36.00 |
Interpace Biosciences has higher revenue and earnings than InspireMD. Interpace Biosciences is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares InspireMD and Interpace Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InspireMD | -413.96% | -69.42% | -57.68% |
| Interpace Biosciences | 65.25% | 219.07% | 105.05% |
Institutional & Insider Ownership
44.8% of InspireMD shares are held by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are held by institutional investors. 34.1% of InspireMD shares are held by company insiders. Comparatively, 5.5% of Interpace Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
InspireMD has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Summary
InspireMD beats Interpace Biosciences on 8 of the 14 factors compared between the two stocks.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
About Interpace Biosciences
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
